MDGL
Madrigal Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-6/100
Last price
496.45
▲ 2.83 (0.57%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
499.00
Prev close
493.62
Day high
504.06
Day low
478.71
Volume
330.28K
Market cap
$11.47B
P/E (TTM)
—
52W range
393.61 – 615.00
Day trading desk
Gap from prior close
+1.09%
Prior close 493.62
VWAP
494.25
+0.45% from price
Relative volume
1.97×
Unusually busy
Session range
5.30%
478.71 – 504.06
Position in range
70%
Mid range
ATR (14D)
15.53
3.13% of price
Prior day high
505.00
PDH
Prior day low
491.25
PDL
Bid / ask spread
—
Quote not published
Session volume
575.70K
Avg 292.63K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.55%
-4.5%
1M
-8.25%
-9.4%
3M
-12.19%
-16.7%
6M
-3.02%
-21.2%
YTD
-14.75%
-29.0%
1Y
+12.06%
-4.4%
3Y
+239.94%
+157.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MDGL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+33.41K
Net buying
Buy transactions
8
54.68K shares
Sell transactions
5
21.27K shares
Net transactions
+13
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
1.35M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 11, 26 | SIBOLD WILLIAM JOHN Chief Executive Officer |
SELL | 11.58K | $6.24M | Direct |
| Aug 17, 26 | KELLEY SHANNON T General Counsel |
SELL | 664 | $341.94K | Direct |
| Aug 14, 26 | REED JOHN C Director |
STOCK | 647 | $0 | Direct |
| Jul 20, 26 | SIBOLD WILLIAM JOHN Chief Executive Officer |
SELL | 2.50K | $1.37M | Direct |
| Jul 17, 26 | SIBOLD WILLIAM JOHN Chief Executive Officer |
— | 50.00K | — | Direct |
| Jun 17, 26 | BRENNAN DANIEL J Director |
STOCK | 404 | $0 | Direct |
| Jun 17, 26 | BAKER BROS ADVISORS, L.P. Unknown |
STOCK | 1.82K | $0 | Indirect |
| Jun 17, 26 | FOUSE JACQUALYN A. Director |
STOCK | 454 | $0 | Direct |
| Jun 17, 26 | TAUB REBECCA A. Director |
STOCK | 454 | $0 | Direct |
| Jun 17, 26 | LEVY RICHARD S Director |
STOCK | 454 | $0 | Direct |
| Jun 17, 26 | DALY JAMES M. Director |
STOCK | 454 | $0 | Direct |
| May 22, 26 | LEVY RICHARD S Director |
SELL | 5.68K | $2.93M | Direct |
| May 18, 26 | SOERGEL DAVID Officer |
SELL | 844 | $435.42K | Direct |
| Mar 6, 26 | TAUB REBECCA A. Director |
SELL | 491 | $212.08K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAKER BROS ADVISORS, L.P. |
Unknown | — | Stock Award(Grant) |
CRAVES FREDERICK B |
Director | 383.55K | Sale |
DIER MARDI C |
Chief Financial Officer | 12.49K | Sale |
FRIEDMAN PAUL A |
Director | 842.70K | Sale |
HUNTSMAN CAROLE A |
Officer | 12.69K | Sale |
KELLEY SHANNON T |
General Counsel | 11.47K | Sale |
LEVY RICHARD S |
Director | 22.47K | Stock Award(Grant) |
SIBOLD WILLIAM JOHN |
Chief Executive Officer | 197.75K | Sale |
SOERGEL DAVID |
Officer | 11.07K | Sale |
TAUB REBECCA A. |
Director | 1.11M | Stock Award(Grant) |
Fundamentals
Market cap$11.47B
Enterprise value$10.98B
Revenue (TTM)$1.28B
Gross profit$1.17B
EBITDA$-321.10M
Net income$-325.10M
EPS (TTM)$-12.92
Free cash flow$-80.47M
Total cash$838.75M
Total debt$347.75M
Book value / share$22.68
Shares outstanding23.10M
Float13.72M
Short % of float11.47%
Dividend yield0.00%
Beta (5Y)-1.05
Valuation & profitability ratios
Trailing P/E—
Forward P/E51.58
PEG ratio—
Price / sales—
Price / book21.89
EV / revenue8.55
EV / EBITDA-34.19
Gross margin91.48%
Operating margin-15.46%
Profit margin-25.32%
Return on equity-53.31%
Return on assets-17.84%
Debt / equity66.40
Current ratio3.21
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $958.40M | $180.13M | $0 | $0 | +432.1% |
| Operating revenue | $958.40M | $180.13M | $0 | $0 | +432.1% |
| Cost of revenue | $56.15M | $6.23M | $0 | $0 | +800.8% |
| Gross profit | $902.25M | $173.90M | $0 | $0 | +418.8% |
| Research & development | $388.52M | $236.72M | $272.35M | $245.44M | +64.1% |
| Selling, general & admin | $813.83M | $435.06M | $108.15M | $48.13M | +87.1% |
| Total operating expense | $1.20B | $671.77M | $380.50M | $293.57M | +79.0% |
| Operating income | -$300.10M | -$497.88M | -$380.50M | -$293.57M | +39.7% |
| Net interest income | $15.05M | $31.98M | $6.87M | -$1.78M | -52.9% |
| Pre-tax income | -$288.28M | -$465.89M | -$373.63M | -$295.35M | +38.1% |
| Net income | -$288.28M | -$465.89M | -$373.63M | -$295.35M | +38.1% |
| Net income to common | -$288.28M | -$465.89M | -$373.63M | -$295.35M | +38.1% |
| Basic EPS | -12.85 | -21.90 | -19.99 | -17.23 | +41.3% |
| Diluted EPS | -12.85 | -21.90 | -19.99 | -17.23 | +41.3% |
| EBIT | -$265.98M | -$451.22M | -$360.92M | -$291.39M | +41.1% |
| EBITDA | -$264.47M | -$450.13M | -$360.39M | -$290.92M | +41.2% |
| Basic shares | 22.43M | 21.27M | 18.69M | 17.14M | +5.5% |
| Diluted shares | 22.43M | 21.27M | 18.69M | 17.14M | +5.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $198.69M | $100.02M | $99.92M | $331.55M | +98.7% |
| Cash & short-term investments | $983.56M | $926.25M | $634.13M | $358.77M | +6.2% |
| Accounts receivable | $134.48M | $53.82M | $0 | — | +149.9% |
| Inventory | $74.84M | $34.07M | $0 | — | +119.7% |
| Total current assets | $1.25B | $1.03B | $637.28M | $361.37M | +20.6% |
| Property, plant & equipment | $6.44M | $4.59M | $3.27M | $1.20M | +40.2% |
| Goodwill & intangibles | $7.38M | $4.73M | $0 | — | +56.1% |
| Total assets | $1.26B | $1.04B | $640.55M | $362.57M | +20.9% |
| Total current liabilities | $310.29M | $169.28M | $118.55M | $115.89M | +83.3% |
| Long-term debt | $339.88M | $117.57M | $115.48M | $49.29M | +189.1% |
| Total debt | $347.63M | $119.57M | $117.19M | $49.89M | +190.7% |
| Total liabilities | $656.90M | $287.86M | $235.21M | $165.18M | +128.2% |
| Retained earnings | -$2.09B | -$1.80B | -$1.34B | -$962.66M | -16.0% |
| Shareholder equity | $602.69M | $754.38M | $405.33M | $197.39M | -20.1% |
| Working capital | $935.48M | $863.65M | $518.73M | $245.47M | +8.3% |
| Net tangible assets | $595.31M | $749.65M | $405.33M | $197.39M | -20.6% |
| Shares issued | 22.84M | 22.00M | 19.88M | 18.10M | +3.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$288.28M | -$465.89M | -$373.63M | -$295.35M | +38.1% |
| Depreciation & amortisation | $1.51M | $1.10M | $527.00K | $467.00K | +37.4% |
| Stock-based compensation | $98.13M | $79.88M | $49.73M | $31.63M | +22.8% |
| Change in working capital | -$8.50M | -$72.34M | -$3.28M | $37.60M | +88.3% |
| Operating cash flow | -$189.55M | -$455.57M | -$324.23M | -$224.86M | +58.4% |
| Capital expenditure | -$3.47M | -$6.46M | -$1.48M | -$217.00K | +46.3% |
| Investing cash flow | $32.32M | -$274.39M | -$502.52M | $206.69M | +111.8% |
| Financing cash flow | $255.98M | $735.06M | $595.12M | $313.45M | -65.2% |
| Free cash flow | -$193.02M | -$462.03M | -$325.71M | -$225.07M | +58.2% |
| End cash position | $203.78M | $105.02M | $99.92M | $331.55M | +94.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $364.25M | $311.34M | $321.08M | $287.27M | $212.80M | +17.0% |
| Operating revenue | $364.25M | $311.34M | $321.08M | $287.27M | $212.80M | +17.0% |
| Cost of revenue | $40.01M | $26.85M | $24.45M | $18.12M | $9.06M | +49.0% |
| Gross profit | $324.25M | $284.49M | $296.63M | $269.15M | $203.74M | +14.0% |
| Research & development | $91.18M | $108.69M | $116.27M | $174.00M | $54.08M | -16.1% |
| Selling, general & admin | $289.38M | $268.52M | $239.98M | $209.12M | $196.86M | +7.8% |
| Total operating expense | $380.55M | $377.21M | $356.24M | $383.12M | $250.94M | +0.9% |
| Operating income | -$56.31M | -$92.72M | -$59.61M | -$113.97M | -$47.20M | +39.3% |
| Net interest income | -$836.00K | $424.00K | $1.16M | $2.86M | $4.96M | -297.2% |
| Pre-tax income | -$57.94M | -$94.39M | -$58.58M | -$114.19M | -$42.28M | +38.6% |
| Net income | -$57.94M | -$94.39M | -$58.58M | -$114.19M | -$42.28M | +38.6% |
| Net income to common | -$57.94M | -$94.39M | -$58.58M | -$114.19M | -$42.28M | +38.6% |
| Basic EPS | -1.99 | -3.25 | -2.57 | -5.08 | -1.50 | +38.8% |
| Diluted EPS | -1.99 | -3.25 | -2.57 | -5.08 | -1.50 | +38.8% |
| EBIT | -$50.00M | -$86.57M | -$50.28M | -$106.74M | -$39.02M | +42.2% |
| EBITDA | -$49.62M | -$86.19M | -$49.89M | -$106.38M | -$38.64M | +42.4% |
| Basic shares | 29.15M | 29.03M | 22.83M | 22.48M | 28.23M | +0.4% |
| Diluted shares | 29.15M | 29.03M | 22.83M | 22.48M | 28.23M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $292.73M | $227.03M | $198.69M | $295.69M | $186.19M | +28.9% |
| Cash & short-term investments | $838.75M | $812.77M | $983.56M | $1.11B | $797.02M | +3.2% |
| Accounts receivable | $192.31M | $187.36M | $134.48M | $113.28M | $79.23M | +2.6% |
| Inventory | $99.39M | $112.07M | $74.84M | $69.32M | $63.50M | -11.3% |
| Total current assets | $1.20B | $1.18B | $1.25B | $1.35B | $1.00B | +1.4% |
| Property, plant & equipment | $17.17M | $14.24M | $6.44M | $8.30M | $7.48M | +20.6% |
| Goodwill & intangibles | $7.19M | $7.28M | $7.38M | $7.48M | $4.55M | -1.3% |
| Total assets | $1.24B | $1.23B | $1.26B | $1.36B | $1.02B | +1.4% |
| Total current liabilities | $374.20M | $338.26M | $310.29M | $391.41M | $196.50M | +10.6% |
| Long-term debt | $340.79M | $340.33M | $339.88M | $339.75M | $118.38M | +0.1% |
| Total debt | $347.75M | $347.31M | $347.63M | $346.40M | $123.95M | +0.1% |
| Total liabilities | $720.92M | $683.87M | $656.90M | $736.73M | $319.40M | +5.4% |
| Retained earnings | -$2.24B | -$2.18B | -$2.09B | -$2.03B | -$1.92B | -2.7% |
| Shareholder equity | $523.72M | $543.45M | $602.69M | $625.73M | $695.98M | -3.6% |
| Working capital | $824.98M | $844.05M | $935.48M | $955.27M | $806.85M | -2.3% |
| Net tangible assets | $516.54M | $536.17M | $595.31M | $618.25M | $691.43M | -3.7% |
| Shares issued | 23.09M | 23.04M | 22.84M | 22.70M | 22.22M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$57.94M | -$94.39M | -$58.58M | -$114.19M | -$42.28M | +38.6% |
| Depreciation & amortisation | $381.00K | $386.00K | $392.00K | $358.00K | $377.00K | -1.3% |
| Stock-based compensation | $35.37M | $34.02M | $25.79M | $26.25M | $25.16M | +4.0% |
| Change in working capital | $33.42M | — | — | — | — | — |
| Operating cash flow | $23.33M | -$167.44M | -$133.46M | $79.85M | -$47.05M | +113.9% |
| Capital expenditure | -$4.25M | -$3.85M | — | — | — | -10.5% |
| Investing cash flow | $34.20M | $192.19M | $27.58M | -$207.00M | $47.86M | -82.2% |
| Financing cash flow | $3.11M | $2.33M | $8.96M | $236.65M | $1.74M | +33.6% |
| Free cash flow | $19.08M | -$171.28M | -$133.07M | $75.99M | -$47.05M | +111.1% |
| End cash position | $292.88M | $232.19M | $203.78M | $300.69M | $191.19M | +26.1% |
Options analytics
Put / call volume
0.16
Call-heavy session
Put / call open interest
0.30
Positioning, not flow
Max pain
500.00
+0.7% from spot
ATM implied vol
56.9%
Nearest strike to spot
Skew (10% OTM)
+2.7%
Puts bid over calls
Call volume
499
Contracts, this expiry
Put volume
79
Contracts, this expiry
Heaviest call OI
520.00
606 contracts
Heaviest put OI
500.00
191 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -2.23 | -1.99 | +10.8% |
| Mar 2026 | -4.14 | -1.38 | +66.7% |
| Dec 2025 | -0.88 | -2.57 | -192.2% |
| Sep 2025 | -1.99 | -4.96 | -148.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.09 | 4 | $405.46M | +41.1% |
| Next quarter | -0.42 | 4 | $445.55M | +38.8% |
| Current year | -6.49 | 4 | $1.53B | +59.4% |
| Next year | 9.63 | 4 | $2.13B | +39.3% |
Analyst targets & ownership
Mean target$682.11
High target$962.00
Low target$543.00
Implied upside37.40%
Analyst count18
ConsensusSTRONG BUY
Strong buy / Buy3 / 15
Hold1
Sell / Strong sell0 / 0
Held by insiders5.83%
Held by institutions104.65%
Institutions holding563
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
506.24
-1.93% from price
SMA 20
518.79
-4.31% from price
SMA 50
521.14
-4.74% from price
SMA 100
519.26
-4.39% from price
SMA 200
510.06
-2.67% from price
EMA 12
507.80
-2.23% from price
EMA 26
516.37
-3.86% from price
EMA 50
520.10
-4.55% from price
RSI (14)
36.3
Neutral
MACD (12,26,9)
-8.57
Hist -3.08
ATR (14)
15.53
3.13% of price
Realised vol 30D
24.6%
Annualised
Bollinger upper
548.71
20, 2σ
Bollinger lower
488.87
20, 2σ
50 / 200 cross
Golden
521.14 vs 510.06
Trend bias
Below 200
-2.67%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.29
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
24.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-29.4%
Peak to trough
Max drawdown 5Y
-61.4%
Peak to trough
ATR 14
15.53
3.13% of price
Beta (reported)
-1.05
5Y monthly, from filing
Short interest
Shares short
2.25M
Prior 2.03M
Change vs prior
+11.3%
Shorts adding
% of float
11.47%
Elevated
% of shares out
9.76%
Against total outstanding
Days to cover
10.2
Crowded exit
Float
13.72M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 26 | Citigroup | INITIATED | — | Buy |
| Aug 4, 26 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Aug 3, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 29, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 27, 26 | Wells Fargo | INITIATED | — | Overweight |
| Jun 11, 26 | B of A Securities | MAINTAINED | Neutral | Neutral |
| May 13, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| May 7, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| May 7, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| May 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 20, 26 | B of A Securities | MAINTAINED | Neutral | Neutral |
| Jan 28, 26 | Barclays | INITIATED | — | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJul 25, 2016
Last split1:35
Split dateJul 25, 2016
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-30
Offering Registrations
S-8 · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-05-06
Proxy Statements
DEF 14A · 2026-04-28
Periodic Financial Reports
10-K · 2026-02-19
Corporate Changes & Voting Matters
8-K · 2026-01-30
Corporate Changes & Voting Matters
8-K · 2025-12-11
Headlines
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
GlobeNewswire · 16h ago
Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target
MT Newswires · 14d ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 20d ago
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
Motley Fool · 26d ago
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
GlobeNewswire · 35d ago
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
Motley Fool · 42d ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 47d ago
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
Zacks · 49d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.